Potential Add-on Treatment for Patients with Parkinson's Disease: Stimvia Completes Pilot Study and Announces Promising Initial Results

Stimvia United Kingdom United States of America France Germany Spain Austria Belgium Italy Netherlands Switzerland Mexico Brazil Argentina Czech Republic New York

reveal that Stimvia's technology is among the most effective in treating conditions like an overactive bladder, which impacts approximately 40 million individuals in the USA.

The company's key technological components and methods are safeguarded by over 100 international patents across the EU, Japan, Russia, and the USA. Furthermore, Stimvia is distinguished by prestigious certifications from the globally respected German institution, TÜV SÜD.

Photo: https://mma.prnewswire.com/media/2432205/Stimvia_URIS.jpg
Logo: https://mma.prnewswire.com/media/2036393/3946833/Stimvia_Logo.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/potential-add-on-treatment-for-patients-with-parkinsons-disease-stimvia-completes-pilot-study-and-announces-promising-initial-results-302166139.html